An individual with CPVT harboring a novel mutation in the type 2 cardiac ryanodine receptor (RyR2) was identified whose persistent ventricular arrhythmias during β-blockade with nadolol were abolished during flecainide treatment. The gene discussed is RYR2; the disease is catecholaminergic polymorphic ventricular tachycardia.